CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*

Download All
Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Engage in this scientific analysis of data presented at IDWeek and HIV Glasgow 2022, with rapid postconference webinars by expert faculty and Capsule Summaries on key HIV prevention and treatment studies and new and investigational ART regimens. Watch the on-demand webinars, download the slides, and gain global perspectives with companion ClinicalThought commentaries.

Highlights

Capsule Summary Slidesets

The broadly neutralizing antibody VH3810109, administered by a single IV infusion, displayed antiviral efficacy and was well tolerated in people with HIV naive to treatment.

Released: November 4, 2022

In expanded multivariable analyses from ATLAS, ATLAS-2M, and FLAIR of PWH receiving LA CAB plus RPV, factors most predictive of confirmed virologic failure were preexisting rilpivirine resistance associated mutations and HIV-1 subtype A6/A1.

Released: October 28, 2022

In models and simulations, islatravir 0.25 mg daily was predicted to have lymphocyte and CD4+ T-cell increases similar to standard ART.

Released: November 1, 2022

LA CAB + RPV was highly effective in US cohort of PWH virologically suppressed at regimen initiation and in a small number of PWH unsuppressed at initiation.

Released: November 1, 2022

Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.

Released: October 26, 2022

At Week 52, maintenance therapy with SC lenacapavir in combination with an optimized background regimen was associated with virologic suppression in 78% of heavily treatment–experienced persons with multidrug-resistant HIV infection.

Released: November 3, 2022

Post hoc analysis evaluated the effect of different islatravir doses on total lymphocyte and CD4+ T-cell and B-cell counts.

Released: November 9, 2022

Efficacy advantage of long-acting CAB over FTC/TDF for HIV PrEP persisted 1 year after unblinding, with 3 new cases of INSTI mutations observed.

Released: October 27, 2022

Investigators state that data support effectiveness, safety, and persistence of BIC/FTC/TAF in treatment-naive and treatment-experienced PWH with a high prevalence of comorbidities at baseline.

Released: November 7, 2022

Despite most survey participants reporting awareness of PrEP with approximately one half aware of LA PrEP, a minority had ever used PrEP and even fewer were currently using PrEP.

Released: October 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings